Prostate Cancer - Results from #26280

Androgen deprivation therapy in prostate cancer: Focusing on sexual side effects - Abstract February 9, 2012

Seven years of experience with high-intensity focused ultrasound for prostate cancer: Advantages and limitations - Abstract February 9, 2012

Distinct redox profiles of selected human prostate carcinoma cell lines: Implications for rational design of redox therapy - Abstract February 8, 2012

Unilateral exophthalmos revealing metastatic prostate cancer - Abstract February 8, 2012

Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era - Abstract February 8, 2012

Understanding variation in primary prostate cancer treatment within the Veterans Health Administration - Abstract February 8, 2012

Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer - Abstract February 8, 2012

Acceptability and preliminary feasibility of an Internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: Randomized pilot study - Abstract February 8, 2012

Explaining racial differences in prostate cancer mortality - Abstract February 8, 2012

Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC Map: A prospective large-scale cohort study - Abstract February 8, 2012

Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood - Abstract February 8, 2012

Adjuvant effect of IV clodronate on the delay of bone metastasis in high-risk prostate cancer patients: A prospective study - Abstract February 8, 2012

Focal therapy for localised prostate cancer: Are we asking the correct research questions? - Abstract February 8, 2012

Detailed results from ALSYMPCA phase III study highlight the positive impact of Alpharadin (radium-223 chloride) on skeletal related events associated with bone metastases from castration resistant prostate cancer February 8, 2012

GU Cancers Symposium 2012 - Prostate cancer: Take home message - Session Highlights February 8, 2012

GU Cancers Symposium 2012 - mCRPC opportunities for the urologist and radiation oncologist: An interview with Adam M. Kibel, Chairman, GU Cancers Symposium - Session Highlights February 8, 2012

GU Cancers Symposium 2012 - Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA) - Session Highlights February 8, 2012

Dietary calcium and risk for prostate cancer: A case-control study among US veterans - Abstract February 7, 2012

Risk profiles of prostate cancers identified from UK primary care using national referral guidelines - Abstract February 7, 2012

BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy - Abstract February 7, 2012

Page 1315 of 1436